Health Care & Life Sciences » Pharmaceuticals | Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
-
-
-
133.00
2,612.00
51,495
Cost of Goods Sold (COGS) incl. D&A
444.00
684.00
1,384.00
-
5,826.00
20,684
Gross Income
444.00
684.00
1,384.00
-
3,214.00
30,811
SG&A Expense
31,836.00
56,094.00
146,354.00
244,716.00
319,728.00
402,184
EBIT
32,280.00
56,778.00
147,738.00
248,007.00
322,942.00
371,373
Unusual Expense
2,901.00
3,324.00
-
-
6,000.00
-
Non Operating Income/Expense
105.00
308.00
200.00
1,621.00
6,530.00
164,734
Pretax Income
35,070.00
59,802.00
145,618.00
245,839.00
318,338.00
197,097
Income Tax
-
-
-
35.00
16,199.00
514
Consolidated Net Income
35,070.00
59,802.00
145,618.00
245,874.00
302,139.00
197,611
Net Income
35,070.00
59,802.00
145,618.00
245,874.00
302,139.00
197,611
Net Income After Extraordinaries
35,070.00
59,802.00
145,618.00
245,874.00
302,139.00
197,611
Net Income Available to Common
50,289.00
64,610.00
145,618.00
245,874.00
302,139.00
197,611
EPS (Basic)
0.00
2.25
3.96
6.21
7.12
3.97
Basic Shares Outstanding
31,663.50
28,755.80
36,782.60
39,586.90
42,453.10
49,775.20
EPS (Diluted)
1.59
2.25
3.96
6.21
7.12
3.97
Diluted Shares Outstanding
31,663.50
28,755.80
36,782.60
39,586.90
42,453.10
49,775.20
EBITDA
31,836.00
56,094.00
146,354.00
244,583.00
317,117.00
351,835
Non-Operating Interest Income
216.00
608.00
2,320.00
3,789.00
4,074.00
9,542
Preferred Dividends
15,219.00
4,808.00
-
-
-
-

About Ultragenyx Pharmaceutical

View Profile
Address
60 Leveroni Court
Novato California 94949
United States
Employees -
Website http://www.ultragenyx.com
Updated 07/08/2019
Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita. The company was founded by Emil D.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.